<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wiedemar N</submitter><funding>Swiss National Science Foundation</funding><funding>Wellcome Trust</funding><pagination>595-608</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6996322</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>1(10)</volume><pubmed_abstract>Suramin was introduced into the clinic a century ago and is still used to treat the first stage of acute human sleeping sickness. Due to its size and sixfold negative charge, uptake is mediated through endocytosis and the suramin receptor in trypanosomes is thought to be the invariant surface glycoprotein 75 (ISG75). Nevertheless, we recently identified a variant surface glycoprotein (VSG&lt;sup>Sur&lt;/sup>) that confers strong in vitro resistance to suramin in a &lt;i>Trypanosoma brucei rhodesiense&lt;/i> line. In this study, we introduced &lt;i>VSG&lt;sup>Sur&lt;/sup>&lt;/i> into the active bloodstream expression site of a &lt;i>T. b. brucei&lt;/i> line. This caused suramin resistance and cross resistance to trypan blue. We quantified the endocytosis of different substrates by flow cytometry and showed that the expr</pubmed_abstract><journal>FASEB bioAdvances</journal><pubmed_title>Expression of a specific variant surface glycoprotein has a major impact on suramin sensitivity and endocytosis in &lt;i>Trypanosoma brucei&lt;/i>.</pubmed_title><pmcid>PMC6996322</pmcid><funding_grant_id>204697/Z/16/Z</funding_grant_id><funding_grant_id>310030</funding_grant_id><funding_grant_id>WTI 204697/Z/16/Z</funding_grant_id><funding_grant_id>156264</funding_grant_id><funding_grant_id>310030_156264</funding_grant_id><pubmed_authors>Field MC</pubmed_authors><pubmed_authors>Cal M</pubmed_authors><pubmed_authors>Maser P</pubmed_authors><pubmed_authors>Zoltner M</pubmed_authors><pubmed_authors>Wiedemar N</pubmed_authors><pubmed_authors>Zwyer M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Expression of a specific variant surface glycoprotein has a major impact on suramin sensitivity and endocytosis in &lt;i>Trypanosoma brucei&lt;/i>.</name><description>Suramin was introduced into the clinic a century ago and is still used to treat the first stage of acute human sleeping sickness. Due to its size and sixfold negative charge, uptake is mediated through endocytosis and the suramin receptor in trypanosomes is thought to be the invariant surface glycoprotein 75 (ISG75). Nevertheless, we recently identified a variant surface glycoprotein (VSG&lt;sup>Sur&lt;/sup>) that confers strong in vitro resistance to suramin in a &lt;i>Trypanosoma brucei rhodesiense&lt;/i> line. In this study, we introduced &lt;i>VSG&lt;sup>Sur&lt;/sup>&lt;/i> into the active bloodstream expression site of a &lt;i>T. b. brucei&lt;/i> line. This caused suramin resistance and cross resistance to trypan blue. We quantified the endocytosis of different substrates by flow cytometry and showed that the expr</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Oct</publication><modification>2025-04-04T03:33:59.783Z</modification><creation>2020-05-22T12:00:33Z</creation></dates><accession>S-EPMC6996322</accession><cross_references><pubmed>32123811</pubmed><doi>10.1096/fba.2019-00033</doi></cross_references></HashMap>